MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants.

Wednesday, Mar 4, 2026 5:23 pm ET1min read
MAIA--

MAIA Biotechnology has commenced an underwritten public offering of common stock and pre-funded warrants. The offering will be offered by the company, with an option to purchase additional shares. The proposed offering is subject to market and other conditions. The offering is intended to raise capital to support the company's clinical-stage biopharmaceutical development for cancer treatments.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet